ABVC BioPharma’s (ABVC) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of ABVC BioPharma (NASDAQ:ABVC) in a research note issued to investors on Friday morning,Weiss Ratings reports.

ABVC BioPharma Stock Up 2.1%

Shares of ABVC stock opened at $2.98 on Friday. ABVC BioPharma has a 12 month low of $0.40 and a 12 month high of $5.48. The firm has a market cap of $70.15 million, a PE ratio of -17.53 and a beta of 0.30. The stock has a 50 day moving average of $2.95 and a 200-day moving average of $2.37.

ABVC BioPharma (NASDAQ:ABVC) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.13) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On ABVC BioPharma

An institutional investor recently raised its position in ABVC BioPharma stock. XTX Topco Ltd increased its position in shares of ABVC BioPharma, Inc. (NASDAQ:ABVC) by 75.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,439 shares of the company’s stock after buying an additional 26,034 shares during the quarter. XTX Topco Ltd owned 0.36% of ABVC BioPharma worth $64,000 at the end of the most recent quarter. Institutional investors own 11.38% of the company’s stock.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.